ArticleAnnals of neurology2024
Relationships of Cognitive Measures with Cerebrospinal Fluid but Not Imaging Biomarkers of Alzheimer Disease Vary between Black and White Individuals.
Article in Annals of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 18 citations in OpenAlex.
- Differences in amyloid PET positivity based on ethnoracial group and social determinants of health: The new IDEAS study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Article
- Diagnostic classifications based on cognitive, CSF, and PET biomarkers across ADNI cohorts: cross-sectional and longitudinal variability.Brain communications · 2026Article
- Fluid biomarkers for neurodegenerative diseases: a comprehensive update.Alzheimer's research & therapy · 2025Review
- Computational whole-body-exposome models for global precision brain health.Nature communications · 2025Article
- Associations of Longitudinal Changes in Blood Biomarkers of Dementia With the Proportion of Genetically Inferred African Ancestry.Neurology · 2025Article
- Person-specific digital measurements of air pollutant exposure and biomarkers of Alzheimer's disease: Findings from a pilot study.Journal of Alzheimer's disease : JAD · 2025Article
- A General Linear Mixed Effect Model to Infer Biomarker Correlations by Bridging Retrospectively Measured Data Across Multiple Studies.Statistics in medicine · 2025Article
- Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- CognivueJournal of Alzheimer's disease : JAD · 2025Article
- Neuroimaging and biofluid biomarkers across race and ethnicity in older adults across the spectrum of cognition.Ageing research reviews · 2024Review
- A Comparative Analysis of Two Automated Quantification Methods for Regional Cerebral Amyloid Retention: PET-Only and PET-and-MRI-Based Methods.International journal of molecular sciences · 2024Article
- Baseline levels and longitudinal changes in plasma Aβ42/40 among Black and white individuals.Nature communications · 2024Article
- Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease.Nature reviews. Neurology · 2024Review
- Navigating complexities of racial disparities in Alzheimer disease biomarkers.Nature reviews. Neurology · 2024Article
- Diversity, equity and inclusion in neurology.Nature reviews. Neurology · 2024Article
- Baseline levels and longitudinal rates of change in plasma Aβ42/40 among self-identified Black/African American and White individuals.Research square · 2024Article
- Population disparities in Alzheimer's disease: A systematic review of fluid and neuroimaging biomarkers.Alzheimer's & dementia (Amsterdam, Netherlands)Review
Corrections and comments
- Commented on by
Authors and funding
36 authors at 8 institutions in 1 country.
Funding
Abstract
objectiveBiomarkers of Alzheimer disease vary between groups of self-identified Black and White individuals in some studies. This study examined whether the relationships between biomarkers or between biomarkers and cognitive measures varied by racialized groups.
methodsCerebrospinal fluid (CSF), amyloid positron emission tomography (PET), and magnetic resonance imaging measures were harmonized across four studies of memory and aging. Spearman correlations between biomarkers and between biomarkers and cognitive measures were calculated within each racialized group, then compared between groups by standard normal tests after Fisher's Z-transformations.
resultsThe harmonized dataset included at least one biomarker measurement from 495 Black and 2,600 White participants. The mean age was similar between racialized groups. However, Black participants were less likely to have cognitive impairment (28% vs 36%) and had less abnormality of some CSF biomarkers including CSF Aβ42/40, total tau, p-tau181, and neurofilament light. CSF Aβ42/40 was negatively correlated with total tau and p-tau181 in both groups, but at a smaller magnitude in Black individuals. CSF Aβ42/40, total tau, and p-tau181 had weaker correlations with cognitive measures, especially episodic memory, in Black than White participants. Correlations of amyloid measures between CSF (Aβ42/40, Aβ42) and PET imaging were also weaker in Black than White participants. Importantly, no differences based on race were found in correlations between different imaging biomarkers, or in correlations between imaging biomarkers and cognitive measures.
interpretationRelationships between CSF biomarkers but not imaging biomarkers varied by racialized groups. Imaging biomarkers performed more consistently across racialized groups in associations with cognitive measures. ANN NEUROL 2024;95:495-506.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.